Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics has $19 highest and $2.5 lowest target. $7.75’s average target is 484.91% above currents $1.325 stock price. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, May 19 by Jefferies. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. The stock has “Outperform” rating by Wells Fargo on Friday, December 4. Jefferies initiated Affimed N.V. (NASDAQ:AFMD) rating on Wednesday, September 9. Jefferies has “Hold” rating and $11 target. As per Thursday, May 19, the company rating was downgraded by Leerink Swann. The stock has “Buy” rating by Laidlaw on Thursday, December 10. The rating was maintained by Oppenheimer on Thursday, August 6 with “Outperform”. The stock of Affimed N.V. (NASDAQ:AFMD) has “Hold” rating given on Thursday, August 31 by Jefferies. The firm has “Hold” rating given on Thursday, September 3 by Zacks. Jefferies maintained Affimed N.V. (NASDAQ:AFMD) on Monday, June 12 with “Hold” rating. See Affimed N.V. (NASDAQ:AFMD) latest ratings:
31/08/2017 Broker: Jefferies Rating: Hold New Target: $2.5 Maintain
01/08/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0000 Maintain
14/07/2017 Broker: SunTrust Rating: Buy New Target: $7 Initiates Coverage On
In analysts report issued on Friday morning, Tritax Big Box Reit Plc (LON:BBOX) stock “Buy” was kept by Analysts at Jefferies International. They currently have a GBX 167.00 target price on the stock. Jefferies International’s target price suggests a potential upside of 11.97% from the company’s last price.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $59.19 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
The stock increased 1.92% or $0.025 during the last trading session, reaching $1.325. About 101,339 shares traded. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since January 12, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.
Tritax Big Box REIT plc is the UK's only Real Estate Investment Trust dedicated to investing in very large Big Box logistics assets in the UK and is committed to delivering attractive and sustainable returns for shareholders. The company has market cap of 2.03 billion GBP. Investing in and actively managing modern standing assets, land suitable for Big Box development and pre-let forward funded developments, the Company focuses on well-located, modern "Big Box" logistics assets, typically greater than 500,000 sq. ft. , let to institutional-grade tenants on long-term leases (typically at least 12 years in length) with upward-only rent reviews and geographic and tenant diversification throughout the UK. It has a 13.31 P/E ratio. The Firm seeks to exploit the significant opportunity in this sub-sector of the UK logistics market owing to strong tenant demand and limited supply of Big Boxes.
Among 4 analysts covering Tritax Big Box Reit Plc (LON:BBOX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Tritax Big Box Reit Plc has GBX 167 highest and GBX 135 lowest target. GBX 148.25’s average target is -0.52% below currents GBX 149.03 stock price. Tritax Big Box Reit Plc had 30 analyst reports since September 21, 2015 according to SRatingsIntel. Jefferies maintained Tritax Big Box REIT plc (LON:BBOX) rating on Friday, August 19. Jefferies has “Buy” rating and GBX 150 target. Liberum Capital maintained it with “Hold” rating and GBX 135 target in Tuesday, October 11 report. Jefferies maintained Tritax Big Box REIT plc (LON:BBOX) on Monday, January 25 with “Buy” rating. The stock of Tritax Big Box REIT plc (LON:BBOX) has “Hold” rating given on Monday, November 20 by Liberum Capital. The firm earned “Hold” rating on Wednesday, October 25 by Liberum Capital. As per Monday, February 15, the company rating was maintained by Jefferies. The stock has “Hold” rating by Liberum Capital on Tuesday, August 1. Jefferies maintained the stock with “Buy” rating in Friday, November 24 report. The stock has “Hold” rating by Numis Securities on Monday, April 24. The stock has “Hold” rating by Numis Securities on Tuesday, August 15.